Clinical Trial Update: The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and immunogenicity of the TB vaccine MVA85A in HIV-infected volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis, HIV Infections | Phase 1 | Status: COMPLETED